Quirós, Luis Pastor, and Rocío Ugalde. “Analysis of the Budgetary Impact of Alemtuzumab As Second-Line Therapy, Compared to Natalizumab and Fingolimod, in Patients Previously Treated With Interferon Beta 1b, Diagnosed With Active Relapsing-Remitting Multiple Sclerosis, Treated in the Costa Rican Social Security Fund”. Global and Regional Health Technology Assessment 6, no. 1 (March 8, 2019). Accessed July 22, 2024. https://journals.aboutscience.eu/index.php/grhta/article/view/467.